The multifunctional solute carrier 3A2 (SLC3A2) confers a poor prognosis in the highly proliferative breast cancer subtypes

[1]  I. Ellis,et al.  MYC regulation of glutamine–proline regulatory axis is key in luminal B breast cancer , 2017, British Journal of Cancer.

[2]  Qing-cheng Yang,et al.  SLC3A2 is upregulated in human osteosarcoma and promotes tumor growth through the PI3K/Akt signaling pathway , 2017, Oncology reports.

[3]  Zhongji Liao,et al.  Endothelial Cells Require CD98 for Efficient Angiogenesis—Brief Report , 2016, Arteriosclerosis, thrombosis, and vascular biology.

[4]  G. Ball,et al.  MYC functions are specific in biological subtypes of breast cancer and confers resistance to endocrine therapy in luminal tumours , 2016, British Journal of Cancer.

[5]  P. Bond.  Regulation of mTORC1 by growth factors, energy status, amino acids and mechanical stimuli at a glance , 2016, Journal of the International Society of Sports Nutrition.

[6]  T. Oyama,et al.  CD98 as a novel prognostic indicator for patients with stage III/IV hypopharyngeal squamous cell carcinoma , 2015, Head & neck.

[7]  I. Ellis,et al.  The mammalian target of rapamycin complex 1 (mTORC1) in breast cancer: the impact of oestrogen receptor and HER2 pathways , 2015, Breast Cancer Research and Treatment.

[8]  E. Rutgers,et al.  Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[9]  I. Ellis,et al.  Biological and clinical significance of PARP1 protein expression in breast cancer , 2014, Breast Cancer Research and Treatment.

[10]  Y. Kanai,et al.  CD98 is a promising prognostic biomarker in biliary tract cancer. , 2014, Hepatobiliary & pancreatic diseases international : HBPD INT.

[11]  D. Sabatini,et al.  Regulation of mTORC1 by amino acids. , 2014, Trends in cell biology.

[12]  G. Prager,et al.  CD98hc (SLC3A2) drives integrin-dependent renal cancer cell behavior , 2013, Molecular Cancer.

[13]  D. Fotiadis,et al.  The SLC3 and SLC7 families of amino acid transporters. , 2013, Molecular aspects of medicine.

[14]  P. Zawierucha,et al.  Microarray-based detection and expression analysis of ABC and SLC transporters in drug-resistant ovarian cancer cell lines. , 2013, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[15]  Carlos Caldas,et al.  A new genome‐driven integrated classification of breast cancer and its implications , 2013, The EMBO journal.

[16]  D. Fotiadis,et al.  The SLC 3 and SLC 7 families of amino acid transporters q , 2013 .

[17]  H. Ashktorab,et al.  Discovery of SLC3A2 cell membrane protein as a potential gastric cancer biomarker: implications in molecular imaging. , 2012, Journal of proteome research.

[18]  F. Markowetz,et al.  The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups , 2012, Nature.

[19]  J. Horiguchi,et al.  Correlation of L‐type amino acid transporter 1 and CD98 expression with triple negative breast cancer prognosis , 2012, Cancer science.

[20]  D. Hanahan,et al.  Hallmarks of Cancer: The Next Generation , 2011, Cell.

[21]  I. Ellis,et al.  Clinicopathologic and molecular significance of phospho-Akt expression in early invasive breast cancer , 2011, Breast Cancer Research and Treatment.

[22]  Andrew R. Green,et al.  MIB1/Ki-67 labelling index can classify grade 2 breast cancer into two clinically distinct subgroups , 2011, Breast Cancer Research and Treatment.

[23]  G. Ball,et al.  Proposal for a modified grading system based on mitotic index and Bcl2 provides objective determination of clinical outcome for patients with breast cancer , 2010, The Journal of pathology.

[24]  N. Sunaga,et al.  Prognostic significance of L-type amino acid transporter 1 (LAT1) and 4F2 heavy chain (CD98) expression in surgically resectable stage III non-small cell lung cancer. , 2010, Experimental and therapeutic medicine.

[25]  I. Ellis,et al.  PIK3CA expression in invasive breast cancer: a biomarker of poor prognosis , 2010, Breast Cancer Research and Treatment.

[26]  G. Ball,et al.  A validated gene expression profile for detecting clinical outcome in breast cancer using artificial neural networks , 2010, Breast Cancer Research and Treatment.

[27]  Mikala Egeblad,et al.  Matrix Crosslinking Forces Tumor Progression by Enhancing Integrin Signaling , 2009, Cell.

[28]  M. Ginsberg,et al.  Dependence of proliferative vascular smooth muscle cells on CD98hc (4F2hc, SLC3A2) , 2009, The Journal of experimental medicine.

[29]  K. Becker,et al.  VEGF-B is dispensable for blood vessel growth but critical for their survival, and VEGF-B targeting inhibits pathological angiogenesis , 2009, Proceedings of the National Academy of Sciences.

[30]  G. Prager,et al.  CD98hc (SLC3A2), a novel marker in renal cell cancer , 2009, European journal of clinical investigation.

[31]  A. Nobel,et al.  Supervised risk predictor of breast cancer based on intrinsic subtypes. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  P. Gout,et al.  The x  c− cystine/glutamate antiporter: A potential target for therapy of cancer and other diseases , 2008, Journal of cellular physiology.

[33]  Jonghwan Kim,et al.  Global Identification of Myc Target Genes Reveals Its Direct Role in Mitochondrial Biogenesis and Its E-Box Usage In Vivo , 2008, PloS one.

[34]  Andrew R. Green,et al.  CCND1 amplification and cyclin D1 expression in breast cancer and their relation with proteomic subgroups and patient outcome , 2008, Breast Cancer Research and Treatment.

[35]  Ian O Ellis,et al.  Biologic and clinical characteristics of breast cancer with single hormone receptor positive phenotype. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[36]  G. Prager,et al.  CD98hc (SLC3A2) Interaction with the Integrin β Subunit Cytoplasmic Domain Mediates Adhesive Signaling* , 2007, Journal of Biological Chemistry.

[37]  S. Esseghir,et al.  Identification of transmembrane proteins as potential prognostic markers and therapeutic targets in breast cancer by a screen for signal sequence encoding transcripts , 2006, The Journal of pathology.

[38]  G. Collins.  The next generation. , 2006, Scientific American.

[39]  G. Ball,et al.  High‐throughput protein expression analysis using tissue microarray technology of a large well‐characterised series identifies biologically distinct classes of breast cancer confirming recent cDNA expression analyses , 2005, International journal of cancer.

[40]  H. Stuhlmann,et al.  CD98hc (SLC3A2) mediates integrin signaling. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[41]  David Carling,et al.  Thr2446 Is a Novel Mammalian Target of Rapamycin (mTOR) Phosphorylation Site Regulated by Nutrient Status* , 2004, Journal of Biological Chemistry.

[42]  I. Ellis,et al.  Expert Commentary. , 2002, Histopathology.

[43]  Christian A. Rees,et al.  Molecular portraits of human breast tumours , 2000, Nature.

[44]  Eiji Takeda,et al.  Expression Cloning and Characterization of a Transporter for Large Neutral Amino Acids Activated by the Heavy Chain of 4F2 Antigen (CD98)* , 1998, The Journal of Biological Chemistry.

[45]  J. Ramos,et al.  Complementation of dominant suppression implicates CD98 in integrin activation , 1997, Nature.

[46]  I. Ellis,et al.  Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. , 2002, Histopathology.

[47]  McCarty Ks.  Histochemical approaches to steroid receptor analyses. , 1984 .

[48]  K. Mccarty,et al.  Histochemical approaches to steroid receptor analyses. , 1984, Seminars in diagnostic pathology.

[49]  Dn Baron,et al.  Molecular Aspects of Medicine , 1981 .